Red Light Therapy and Multiple Sclerosis: A Promising New Frontier
We aren’t making any claims in this article; we are simply sharing research.
Could red light therapy support multiple sclerosis care? Discover its potential role in reducing inflammation and improving quality of life.
Multiple sclerosis (MS) is a complex and deeply challenging condition. It often appears early in adulthood, commonly between the 20's and 40's, and follows a progressive course. At present, there is no way to reverse the disease, and for many people its impact increases over time.
MS is also unpredictable. Symptoms can fluctuate, remain invisible to others, and affect nearly every aspect of life. Physical limitations, cognitive strain, emotional stress, and social challenges often overlap, creating a burden that extends far beyond what’s visible on the surface.
Clearly, better supportive strategies are needed.
That naturally raises the question: Could red light therapy play a role in MS care?
The emerging answer is encouraging. A growing body of research suggests that red light therapy may offer meaningful benefits for people with MS, particularly in areas like inflammation, cellular energy, and overall quality of life. While more research is still needed to clarify optimal protocols and dosing, the science so far is promising. This article explores that evidence in depth and examines how red light therapy and specific devices may fit into a broader MS support strategy.
Introduction into Multiple Sclerosis
First, let’s lay the groundwork by covering the fundamentals of multiple sclerosis. This introduction draws on review papers published within the last five years, which integrate and evaluate large bodies of earlier research into a coherent overview of the disease (1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13).
Building a solid understanding of MS is essential. Once the core disease mechanisms are clear, it becomes much easier to understand why light therapy is being explored as a potential supportive strategy for multiple sclerosis and how it may fit into a broader treatment framework.
The Basics
Multiple Sclerosis (MS) is an autoimmune condition(1). In autoimmune diseases, the immune system mistakenly turns against the body’s own tissues, failing to distinguish between “self” and “non-self.” Instead of targeting true threats like bacteria or viruses, immune activity becomes misdirected toward healthy cells.
In MS, the immune system primarily attacks the myelin sheath of the nervous system (14). Myelin is essential for efficient nerve signaling. It acts like insulation around nerve fibers, dramatically increasing signal speed and accuracy. In many ways, myelin functions as the high-speed highway that allows the brain, spinal cord, and body to communicate effectively.
When myelin in the brain and spinal cord is damaged, nerve conduction slows and signaling becomes disrupted. This leads to impaired communication between the brain, spine, and peripheral nerves. Over time, repeated injury can result in scar tissue formation, known as sclerosis, which may cause lasting or permanent nerve damage.
MS is one of the leading neurodegenerative diseases affecting young adults (1). Its development is influenced by both genetic susceptibility and environmental factors. One of the strongest environmental risk patterns involves latitude, or distance from the equator, which closely tracks with vitamin D status (15; 16; 17; 18; 19). This relationship suggests that sunlight exposure plays a significant role not only in MS risk, but potentially in symptom modulation as well which is an important theme that will be explored later.
Diagnosing MS: From Clinical Criteria to Disease Subtypes
The ability to diagnose multiple sclerosis (MS) has improved dramatically over the past few decades, largely due to major advances in MRI technology (1). Modern MRI scans are not only more sensitive, but also easier to interpret, allowing clinicians to detect MS-related changes earlier and tailor treatment strategies more precisely.
That said, diagnosing MS is still far from straightforward (14). Many MS symptoms overlap with those of other neurological conditions, which means diagnosis requires a comprehensive and careful evaluation. This typically includes a detailed medical history, MRI imaging, neurological examinations, nerve conduction studies, and, in some cases, a lumbar puncture to analyze cerebrospinal fluid (14).
MS is also not a single, uniform disease. Several clinical subtypes exist. The most common form is Relapsing-Remitting MS (RRMS),characterized by periods of symptom flare-ups followed by phases of partial or full recovery. Approximately 80% of people with MS are initially diagnosed with RRMS (2).
Other forms are progressive in nature, meaning symptoms worsen steadily over time. These include Primary Progressive MS (PPMS) and Secondary Progressive MS (SPMS). In PPMS, neurological decline occurs gradually from the onset of the disease, without clear relapses or remissions (2; 8). SPMS, on the otherhand, typically develops after an initial relapsing-remitting phase and may still include intermittent relapses, especially early on (20).
About 15% of individuals with MS are diagnosed with the primary progressive form (2). However, there is ongoing debate in the scientific and clinical communities about how best to define and categorize these MS subtypes, particularly when it comes to distinguishing the transition into SPMS.
"…definitive clinical, imaging, immunologic, orpathologic criteria that demarcate the transition from relapsing-remitting MS to SPMS" (8)
Relapses are critically important, because even when symptoms largely improve, many patients do not return to their previous baseline level of health. Instead, each relapse can leave behind subtle but lasting deficits. This makes early detection, ongoing monitoring, and proper management of MS symptoms essential for preserving long-term function and quality of life.
The Symptoms of MS
The following passage is helpful in understanding the symptoms of MS. The:
"…condition manifests with a wide range of neurological symptoms, such as vision impairment, numbness and tingling, focal weakness, bladder and bowel dysfunction, and cognitive impairment." (2)
The same applies to neuropathic pain, which is a common and often debilitating symptom of multiple sclerosis (13). In essence, many MS symptoms stem from progressive deterioration of nervous system function.
One important aspect not always emphasized in symptom lists is the gradual loss of functional capacity and motor coordination. As MS progresses, the ability to move efficiently and confidently often declines.
Reduced movement capacity can create downstream problems over time. Limited mobility contributes to muscle loss, reduced bone density, poorer motor control, and declining balance. Once these systems begin to deteriorate, broader aspects of health are affected as well, creating a cascade that extends far beyond the nervous system alone.
Treatment:
So what can be done? The reality is that there is currently no definitive cure for multiple sclerosis. However, a range of treatments does exist. These include disease-modifying therapies (DMTs), medications such as corticosteroids, and targeted symptom-management strategies that can slow disease progression and help preserve function.
Timing matters. Early diagnosis and early intervention are consistently associated with better outcomes. The longer MS remains undetected or untreated, the more likely long-term damage becomes.
MS often includes a “prodromal” phase, during which classic neurological symptoms have not yet fully emerged. During this period, individuals may experience more generalized issues such as fatigue, depression, anxiety, migraines, sleep disturbances, and cognitive changes. Clear neurological deficits may be mild or absent at this stage.
Importantly, this early window may represent a critical opportunity. Intervening before significant nervous system damage occurs can place individuals in a far stronger position over the long term.
And this is where the conversation becomes especially interesting:
"The large portfolio of currently available medications paved the way for personalized therapeutic strategies that will balance safety and effectiveness. Incorporation of cognitive interventions, lifestyle recommendations, and management of non-neurological comorbidities could further improve quality of life and outcomes." (1)
Lifestyle choices play a meaningful role in managing multiple sclerosis. Regular physical activity, structured exercise, and a well-balanced diet are all strongly associated with better symptom management and overall function in people with MS (20). Engaging in cognitively demanding activities is equally important. Challenging the brain helps preserve neural resilience, supports cognitive reserve, and may slow functional decline (20).
That said, MS is a complex condition, and lifestyle strategies alone are rarely sufficient to fully address the wide range of symptoms. The broader picture of effective symptom management is more nuanced, as researchers note:
"The treatment plan for individuals with MS includes managing acute episodes, using disease-modifying agents to decrease MS biological function of MS, and providing symptom relief. Management of spasticity requires physiotherapy, prescription of initial drugs such as baclofen or gabapentin, secondary drug options such as tizanidine ordantrolene, and third-line treatment such as benzodiazepines. To treat urinary incontinence some options include anticholinergic medications such asoxybutynin hydrochloride, tricyclic antidepressants (such as amitriptyline), and intermittent self-catheterization. When it comes to bowel problems, one cantry to implement stool softeners and consume a high roughage diet" (4).
This highlights just how complex MS truly is (7). On top of that, emerging biomedical strategies, such as stem cell–based therapies, are now being explored as potential treatment avenues (9). Treatment approaches also differ depending on age, with younger and older individuals responding differently to interventions (10).
Medication remains a cornerstone of MS care, as disease-modifying therapies can reduce relapse rates by roughly 30–70% and slow disease progression in many patients (first-hand clinical evidence).
Ultimately, MS does not affect the nervous system in a single, uniform way. Each impaired function—whether bladder control, mobility, vision, or coordination—requires targeted symptom-specific treatment strategies to achieve the best possible outcomes.
Risk Factors
So, how can MS risk be reduced? As noted earlier, low sunlight exposure and insufficient vitamin D levels are well-established risk factors for MS. Cigarette smoking is another significant contributor to increased risk (20, 25). Maintaining a healthy body weight also appears important, particularly after an MS diagnosis, as excess body fat can worsen disease outcomes (6, 21). Notably, being overweight or obese during childhood may already increase MS risk later in life(23).
Despite growing awareness, the global incidence of MS continues to rise, meaning a larger proportion of people are affected each year worldwide (5). Some risk factors are far more difficult to control. Head trauma, for example, has been associated with an increased risk of developing MS (22). Biological sex is another non-modifiable factor, with women affected roughly two to three times more often than men. Certain viral infections, most notably Epstein–Barr virus, are also strongly linked to MS risk and are challenging to avoid entirely (24).
Next, it’s essential to examine the central role of inflammation in MS, a topic that becomes especially important when discussing how red light therapy may influence disease processes later on.
Inflammation: A Key Driver of Multiple Sclerosis
An overactive immune system is a central driver of multiple sclerosis, and inflammation is the natural consequence of that immune activation (26; 27; 28; 29; 30; 31). This matters deeply because one of the best-studied mechanisms of red light therapy is its ability to reduce systemic and neural inflammation. That connection helps explain why light-based interventions are being explored so seriously in MS research.
At the core of MS lies neuroinflammation, meaning inflammation of the brain and nervous system. In MS, a chronic immune response mistakenly targets the myelin sheath. Myelin can be thought of as the high-speed insulation around nerves, allowing signals to travel quickly and efficiently while also protecting the nerve fibers themselves.
Multiple components of the immune system are involved in this autoimmune cascade. T cells and B cells mistakenly attack myelin, while pro-inflammatory signaling molecules, including TNF-α, interleukin-6, and interferon-gamma (IFN-γ), amplify the inflammatory response. Over time, this sustained inflammation disrupts nerve signaling, damages myelin, and eventually leads to nerve cell death.
As nerve cells degenerate, lesions form in the brain and spinal cord, and disability gradually accumulates. At present, this process cannot be fully reversed. Available treatments aim to slow progression rather than restore lost function. That reality highlights a critical insight: any intervention capable of calming immune overactivation and reducing inflammation has the potential to meaningfully shift MS outcomes.
This is precisely why inflammation is such an important focus. In the next section, this pathway will be explored further in the context of emerging light-based therapies.
Red Light Therapy and the Nervous System: What the Research Suggests
Human Studies:
First, it makes sense to look at the human studies on multiple sclerosis directly, before zooming out to the review papers.
- The first publication focuses on muscle function in people with MS (33). Interestingly, it actually contains two separate studies within the same paper. In both, participants performed maximal muscle contractions of the tibialis anterior, the muscle along the front of the lower leg that plays a key role in walking and balance. Here’s how the (somewhat complex) study design was set up:
"This study consisted of two parts with a randomized double-blind crossover design. In study I, muscle function was assessed in four sessions before and after [red light therapy] in ambulatory pwMS (N = 17, F =14) as follows: maximal voluntary contraction (MVC) and muscle fatigue of the right tibialis anterior (TA) muscle was compared at baseline and following a two-min submaximal fatiguing contraction. Then, [red light therapy] was administered to the belly of TA muscle at different doses of energy of an active device (40 J, 80 J, 120 J) or placebo. The muscle function assessment was then repeated." (33).
- The takeaway from this first study is that muscle performance improved and force returned more quickly when red light therapy was applied (33). The main limitation, however, is methodological: the researchers did not clearly report key treatment parameters, such as the exact wavelength used or the size of the treated area. That makes the results harder to interpret or replicate.
- Next, there’s a second study with a particularly interesting design. In this experiment, one group received light therapy under the tongue, while another group was treated at the radial artery of the forearm (34). The wavelength used was 808 nm, but once again, the total treatment area and dosing details were poorly described. Fatigue levels did not improve in this study, and notably, there was no clearly defined placebo group. This makes it difficult to draw firm conclusions, even though the concept itself is intriguing.
- A third human study also used 808 nm light and followed a similar treatment approach in terms of application sites (35). This time, the results were more compelling: levels of interleukin-10, a key anti-inflammatory cytokine, increased significantly. That finding is particularly relevant for MS, given the central role of chronic inflammation in the disease process.
- Another human study explored four different therapeutic approaches: red light therapy alone, red light therapy combined with magnetic therapy, magnetic therapy alone, and movement-based therapy (36). While the study design leaves room for improvement from a methodological perspective, it offers an encouraging signal. The combination of red light therapy and magnetic therapy produced the strongest outcomes, with meaningful improvements in functional status and likely quality of life. Importantly, these benefits persisted even after the treatment period ended, suggesting potential lasting effects rather than short-term symptom relief. The intervention used a 650 nm red light source, applied in a localized, spot-based manner, which may actually underestimate the full potential of broader or optimized treatment protocols.
- In addition, one more human study exists, although it provides limited methodological detail, making firm conclusions difficult (37). Even so, its inclusion highlights growing clinical interest in light-based approaches for MS and underscores the need for larger, more rigorous trials building on these early signals.
The human evidence base for red light therapy in MS is still quite small, however; the overall trend suggests positive benefits.
Animal Studies
Because there are less human studies available, it’s helpful to look at animal studies to better understand how red light therapy may influence multiple sclerosis. These models allow researchers to explore mechanisms in more controlled settings. Here’s what animal research shows so far:
- First, a mouse study using 660 nm and 850 nm light demonstrated meaningful reductions in inflammation, along with improvements in both sensory and motor function (38). Red light therapy also appeared to have neuroprotective effects, supporting a healthier and more balanced immune response. In this study, light was applied to the animals’ abdomens and backs, allowing for treatment of relatively large surface areas rather than small, localized spots (39).
- Next, an 808 nm study delivered a total dose of 36 J/cm² and focusedspecifically on demyelination, the core pathological process in MS where the myelin sheath of nerves is damaged (40). The mice received six transcranial light therapy sessions over four weeks, with an additional treatment point located between the eyes. The outcomes were particularly compelling, as researchers reported the following:
"Twenty-four hours after the last laser session, all animals were euthanized, and brains were extracted. Serum was obtained for lactate dehydrogenase toxicity testing. Histomorphology analyses consisted of Luxol Fast Blue staining and immunohistochemistry. The results showed thatlaser-treated animals presented motor performance improvement, attenuation of demyelination, increased number of oligodendrocyte precursor cells, modulated microglialand astrocytes activation, and a milder toxicity by cuprizone. Although further studies are required, it is suggested that LLLT represents a feasible therapy for demyelinating diseases." (40).
- Next, a study compared 660 nm and 904 nm light applied directly to the spinal cord in mice (41). The results were encouraging: neuroinflammation decreased, and key disease-driving processes underlying MS were reduced. Once again, this points toward a meaningful biological effect rather than a placebo response.
- Another mouse study used 670 nm light and focused on protecting the nervous system from cellular stress (42). In this case, red light therapy reduced damage caused by Reactive Nitrogen Species, which are closely tied to inflammation and neurodegeneration. Even more importantly, neuronal cell survival improved—an outcome that’s highly relevant for a disease defined by progressive nerve damage.
- Finally, one more 670 nm mouse study further explored these protective effects (43). The researchers used the following treatment protocol:
" Mice received 670 nm light or no light treatment(sham) administered as suppression and treatment protocols. 670 nm light reduced disease severity with both protocols compared to sham treated mice. Disease amelioration was associated with down-regulation of proinflammatory cytokines (interferon-γ, tumor necrosis factor-α) and up-regulation of anti-inflammatory cytokines (IL-4, IL-10) in vitro and in vivo." (43)
- Once again, the takeaway is consistent: inflammation drops across the board, alongside improvements in overall nervous system health.
That brings us the current animal studies on red light therapy for multiple sclerosis. Taken together, they paint a coherent picture. Across different wavelengths and protocols, red light therapy repeatedly shows benefits for neuroinflammation, immune regulation, and neural protection.
I won’t dive into the in-vitro (“in the glass”) studies here. Those Petri-dish experiments are useful for understanding mechanisms, but at this point, we already have a solid foundation from animal and emerging human data.
Finally, let’s step back and look at the review papers - studies that synthesize and evaluate the highest-quality evidence available so far:
MS Reviews
To wrap up this section, let’s turn to what the review literature says about red light therapy for multiple sclerosis. Reviews are especially valuable here because they don’t just summarize results. They critically evaluate patterns, limitations, and biological meaning across many studies.
Below are the four most recent reviews examining red light therapy in the context of MS (44; 45; 46; 47).
The first review focuses entirely on animal models and concludes that the experimental autoimmune encephalomyelitis(EAE) process, commonly used as a close analogue of human MS, is significantly suppressed by red light therapy (44). In addition to reducing disease severity, the authors highlight improvements in several underlying biological mechanisms relevant to MS. Here’s how the researchers describe those deeper processes:
"[Red light therapy] also significantly reduced other parameters such as infiltration of mononuclear cells, [central nervous system] demyelination, apoptosis markers and pro-inflammatory cytokines. However, there was an overall high risk of bias in all of the studies." (44).
Overall, these are great benefits!
The second review on human studies arrives at a similar conclusion and states the following:
"The reviewed studies showed that [red light therapy] modulates brain markers linked to inflammation, oxidative stress, and apoptosis. Improvements in motor, sensorial, and cognitive functions in MS patients were also observed after [red light therapy] therapy. No study reported adverse effects of [red light therapy]." (45)
Encouragingly, this review highlights growing interest and momentum in this area, while also noting that further research will help clarify optimal protocols and applications for MS (45). The third review echoes this positive trajectory and arrives at a similar conclusion:
"[Red light therapy] has positive effects on MS by regulating the inflammatory process, controlling immune cell activity and mitochondrial functions, as well as inhibiting free radicals production which finally leads to a reduction in neurological defects and an improvement in the functional status of patients" (46)
The fourth review reports meaningful reductions in inflammatory activity alongside improved regenerative capacity of neurons, indicating a healthier, more resilient nervous system. This is an encouraging and biologically meaningful finding.
Taken together, the available reviews align closely in their conclusions and consistently point toward beneficial effects. While additional high-quality, long-term human studies will further strengthen the evidence base, the current findings already provide a strong foundation and a clear signal that this field is worth expanding. The science is moving in a promising direction, and future research has substantial potential to refine and optimize these approaches even further.
Red Light Therapy and MS: Targeting the Disease at Its Roots
Current research strongly suggests that red light therapymay positively influence several of the core biological mechanisms involved in multiple sclerosis, particularly those affecting nervous system function.
- Human studies already point to meaningful improvements in muscle performance, an area frequently compromised in MS, along with clear anti-inflammatory effects. While these studies are still limited in number, their consistency is encouraging.
- Animal research allows for a deeper look at what’s happening inside the nervous system and paints an even more optimistic picture. These studies show reductions in both systemic inflammation and neuroinflammation, slowed neurodegeneration and demyelination of myelin-rich white matter, and noticeable improvements in sensory and motor function. Additional benefits include improved immune system regulation, a key issue in autoimmune diseases, and reduced oxidative stress, both of which support long-term neurological resilience.
- Importantly, systematic reviews that synthesize this growing body of evidence largely reinforce these findings, suggesting that the observed benefits are not isolated results but part of a broader, repeatable pattern.
Taken together, the science increasingly indicates that red light therapy may address several underlying drivers of MS rather than merely managing symptoms. While further high-quality human trials will help refine protocols and optimize dosing, the existing evidence provides strong momentum and a compelling case for continued exploration.
Next, let’s look at how red light therapy can be thoughtfully and safely implemented as part of a broader MS management strategy.
Conclusion
The encouraging results from human studies and especially the animal research support an optimistic outlook on red light therapy for MS. Starting slowly and using low doses of red light therapy appears to be a sensible way for people with MS to explore its potential benefits.
More broadly, the outlook for MS continues to improve. With new therapies steadily emerging and red light therapy showing meaningful promise across several neurodegenerative conditions, the future holds increasing options for symptom management and neurological support. As research advances over the coming years and decades, individuals living with MS may have access to more effective, accessible, and empowering tools than ever before.